Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte (PCVX) appointed Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer and tightened guidance for the VAX-31 adult Phase 3 OPUS-1 topline readout to the end of October 2026.
Jodar previously served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases at Pfizer, where he helped lead clinical development and medical affairs for pneumococcal conjugate vaccines Prevnar 13 and Prevnar 20, as well as other major vaccine and antiviral programs. McAvoy most recently led a 235-person legal, compliance and government affairs organization at Teva and has prior experience steering biopharma companies through IPOs and a $2.1 billion acquisition.
The VAX-31 adult Phase 3 OPUS program includes three fully enrolled trials (OPUS-1, OPUS-2 and OPUS-3), with 6,191 adults dosed, about 3,500 of whom received VAX-31. Additional OPUS-2 and OPUS-3 data are anticipated in the first half of 2027.
Vaxcyte (Nasdaq: PCVX) announced that its management will take part in fireside chats and one-on-one meetings at two investor events: the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026, and the Cantor Global Healthcare Conference on September 9-11, 2026. Webcasts of both fireside chats will be available on Vaxcyte’s investor website for about 30 days after each conference.
Vaxcyte (Nasdaq: PCVX) reported second quarter 2026 results and pipeline progress. Cash, cash equivalents and investments totaled $2.51 billion at June 30, 2026, up from $2.44 billion at year-end 2025. R&D expenses were $267.9 million and G&A expenses were $34.9 million, leading to a quarterly net loss of $284.3 million, versus $166.6 million a year earlier.
All three adult Phase 3 OPUS trials of VAX-31 are fully enrolled with 6,191 adults dosed, and topline OPUS-1 data are expected in Q4 2026, with OPUS-2 and OPUS-3 readouts in the first half of 2027. The VAX-31 infant Phase 2 study is fully enrolled, with topline primary series and booster data expected by the end of the first half of 2027. Vaxcyte also initiated a Phase 1 study of VAX-A1 for Group A Streptococcus, with topline data planned for the second half of 2027, and appointed vaccine industry veterans Moncef Slaoui and John Markels to its board.
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine company, announced participation in two July 2026 investor conferences. Management will attend the Leerink Partners Therapeutics Forum with one-on-one meetings on July 15, and the BTIG Virtual Biotechnology Conference with one-on-one meetings on July 28.
Vaxcyte (Nasdaq: PCVX) dosed the first participant in its Phase 1, first-in-human study of VAX-A1, a prophylactic vaccine candidate against Group A Streptococcus, in healthy adults aged 18–40. The randomized, placebo-controlled trial will assess safety, tolerability and initial immune responses, with topline data expected in 2H 2027.
Vaxcyte (Nasdaq: PCVX) reported Q1 2026 results and a business update. As of March 31, 2026, cash, cash equivalents and investments totaled $2.74 billion. Enrollment is complete for three VAX-31 adult Phase 3 OPUS trials (6,191 adults dosed). OPUS-1 topline data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027. Infant Phase 2 enrollment completed (900 infants); infant readouts expected by end of H1 2027. Company plans to start a Phase 1 adult study for VAX-A1 in mid-2026. Q1 R&D expense was $312.8 million and net loss was $320.6 million.
Vaxcyte (Nasdaq: PCVX) said management will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast will be available on the company investor site, with a replay for ~30 days.
Vaxcyte (Nasdaq: PCVX) completed enrollment in its VAX-31 Phase 3 program: OPUS-1 (~4,000 participants) and OPUS-2 (~1,300 participants). OPUS-3 enrollment is ongoing. The program was designed with FDA alignment to support a planned BLA. Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 results expected H1 2027.
VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease and pneumonia in adults.
Vaxcyte (Nasdaq: PCVX) announced publication of positive Phase 1/2 adult data for VAX-31 in The Lancet Infectious Diseases on March 18, 2026. The VAX-31 High Dose met or exceeded OPA non-inferiority for 20 shared serotypes and met superiority for 11 incremental serotypes versus PCV20.
VAX-31 showed robust OPA and IgG responses across all 31 serotypes, a safety profile similar to Prevnar 20, and is being evaluated in the OPUS Phase 3 adult program with topline data expected in Q4 2026.
Vaxcyte (Nasdaq: PCVX) reported fourth-quarter and full-year 2025 results and provided a business update on Feb 24, 2026. The company has ~$2.44 billion in cash and investments at year-end, completed a $632.5M public offering in Feb 2026, advanced a three-trial VAX-31 Phase 3 adult program, completed VAX-31 infant enrollment (900 infants), and finished a Lonza manufacturing buildout to support potential commercialization.